Best overall response (n = 84)
| Treatment . | N . | CR . | PR . | MR . | SD . | PD . | NE . | ORR . | CBR . |
|---|---|---|---|---|---|---|---|---|---|
| Selinexor alone | 57 | — | 2 (4%) | 10 (18%) | 18 (32%) | 17 (30%) | 10 (18%) | 2 (4%) | 12 (21%) |
| Selinexor 45 mg/m2 + dex 20 mg | 12 | 1 (8%) | 5 (42%) | 1 (8%) | 3 (25%) | 1 (8%) | 1 (8%) | 6 (50%) | 7 (58%) |
| Selinexor 60 mg/m2 + dex 20 mg | 15 | — | — | 2 (13%) | 5 (33%) | 5 (33%) | 3 (20%) | 0 (0%) | 2 (13%) |
| All patients | 84 | 1 (1%) | 7 (8%) | 13 (15%) | 26 (31%) | 23 (27%) | 14 (17%) | 8 (10%) | 21 (25%) |
| Treatment . | N . | CR . | PR . | MR . | SD . | PD . | NE . | ORR . | CBR . |
|---|---|---|---|---|---|---|---|---|---|
| Selinexor alone | 57 | — | 2 (4%) | 10 (18%) | 18 (32%) | 17 (30%) | 10 (18%) | 2 (4%) | 12 (21%) |
| Selinexor 45 mg/m2 + dex 20 mg | 12 | 1 (8%) | 5 (42%) | 1 (8%) | 3 (25%) | 1 (8%) | 1 (8%) | 6 (50%) | 7 (58%) |
| Selinexor 60 mg/m2 + dex 20 mg | 15 | — | — | 2 (13%) | 5 (33%) | 5 (33%) | 3 (20%) | 0 (0%) | 2 (13%) |
| All patients | 84 | 1 (1%) | 7 (8%) | 13 (15%) | 26 (31%) | 23 (27%) | 14 (17%) | 8 (10%) | 21 (25%) |
Fourteen patients were considered NE based on withdrawal from study before disease assessment with no evidence of disease progression (n = 8), early death from infection deemed unrelated to treatment (n = 2), and protocol violation (received concomitant antimyeloma therapy, n = 4), but were considered as treatment failures by intent-to-treat.
N, number of all patients within each group (evaluable and nonevaluable); PD, progressive disease; SD, stable disease.